Abstract: The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
September 8, 2015
Assignee:
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
August 25, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
August 25, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: This invention relates to a dental appliance cleanser which is a metastable emulsion comprising about 50-99% w/w of an aqueous phase, about 1-50% w/w of a water immiscible oily phase, the oily phase having a combination of a one or more immiscible oils and one or more flavor oils. The dental appliance cleanser is applied to the dental appliance, outside the wearer's mouth, in the form of an aerated foam.
Type:
Grant
Filed:
March 22, 2007
Date of Patent:
August 18, 2015
Assignee:
GlaxoSmithKline, LLC
Inventors:
Kyle N Brogden, Stanley J. Lech, Narcsh I. Mehta, Philip J. Oths
Abstract: The present invention is related to a dispenser, which is filled with a gel comprising a C1 to C10 carboxylic acid and a thickener, comprising a polyester membrane. The invention further relates to said gel. It also relates to s method for preparing said dispenser, comprising a) mixing C1 to C10 carboxylic acid and the thickener, and b) filling the mixture of step a) into the dispenser. The invention further relates to a method for the control of mites in bee hives comprising putting said dispenser inside or near a bee hive. It also relates to a use of the dispenser or the gel for the control of mites or of nosema in agricultural, industrial or domestic environment.
Type:
Grant
Filed:
September 1, 2010
Date of Patent:
August 11, 2015
Assignee:
BASF SE
Inventors:
David VanderDussen, Renate Wapenhensch, Markus Gewehr, Marco Candolfi, Roland Becker, Sandrine Leblond, Jean-Marc Petat, Nicole Hanewald, Tobias Huth
Abstract: The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
Abstract: A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.
Type:
Grant
Filed:
May 29, 2009
Date of Patent:
June 30, 2015
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Paul F. Lambert, Paul G. Ahlquist, Dohun Pyeon, Hao Shun Huang
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
April 21, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
April 14, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.
Type:
Grant
Filed:
August 24, 2010
Date of Patent:
April 7, 2015
Inventors:
Thomas Moest, Manfred Kurfürst, Walter Doleschal
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
March 31, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: The invention concerns the use of a deoxy hesperetin dihydrochalcone or a salt of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of a plurality of salts of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of deoxy hesperetin dihydrochalcone (I) and a salt or a plurality of salts of the deoxy hesperetin dihydrochalcone (I), to influence the strength of taste impressions of sweet-tasting, unpleasant-, in particular bitter-, tasting or both sweet- and unpleasant-, in particular bitter-, tasting substances or mixtures of substances.
Type:
Grant
Filed:
February 1, 2011
Date of Patent:
March 31, 2015
Assignee:
SYMRISE AG
Inventors:
Michael Backes, Tobias Vössing, Jakob Peter Ley, Susanne Paetz
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
September 3, 2014
Date of Patent:
March 31, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: The invention relates to a method for making a composite material including a porous polymer matrix containing HEMA monomers and in which silver nanoparticles are dispersed, and to the use thereof as an anti-microbial material.
Type:
Grant
Filed:
February 3, 2009
Date of Patent:
March 24, 2015
Assignees:
Centre National de la Recherche Scientifique, Universite d'Orleans
Inventors:
Roland Benoit, Marie-Louise Saboungi, Fabienne Brulé
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
March 24, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.
Type:
Grant
Filed:
June 18, 2010
Date of Patent:
March 24, 2015
Assignee:
Altos Vision Limited
Inventors:
Clive H. Reading, Thomas Rowe, Mario G. Fsadni, Rick Coulon
Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl)nortropane.
Type:
Grant
Filed:
October 2, 2013
Date of Patent:
March 24, 2015
Assignee:
Alseres Pharmaceuticals, Inc.
Inventors:
Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
March 24, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio
Abstract: The present invention relates to a cosmetic or pharmaceutical composition for cutaneous application, whose goal is the depigmentation of the skin.
Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
January 13, 2015
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio